- 英文名称2,4,6-Trichloroquinazoline
- 中文名称2,4,6-三氯喹唑啉
- IUPAC名称2,4,6-trichloroquinazoline
- 其它别名2,4,6-三氯间二氮杂萘; 2,4,6-Trichlroquinazoline
- CAS编号20028-68-6
- MFCD编号:MFCD08445622
- EINECS号:640-885-6
- 分子式:C8H3Cl3N2
- 分子量:233.49
- 产品CID: 1018080
- 产品分类有机原料→分子砌块→芳杂环类化合物→喹唑啉类化合物
欧盟法规
ECHA物质C&L通报2,2,2-Trifluoro-N-(2-Iodo-4-Chlorophenyl)Acetamide置于potassium Carbonate体系中,用 甲醇,N,N-二甲基甲酰胺,乙腈 用作溶剂,化学反应 24.5H,反应生成2,4,6-三氯喹唑啉
参考文献:乙腈介导的 2-乙炔苯胺合成 2,4-二氯喹啉和邻氨基苯甲腈合成 2,4-二氯喹唑啉
标题:乙腈介导的 2-乙炔苯胺合成 2,4-二氯喹啉和邻氨基苯甲腈合成 2,4-二氯喹唑啉
摘要:2,4-二氯喹啉和 2,4-二氯喹唑啉分别由 2-乙炔基苯胺和邻氨基苯甲腈合成,在乙腈中使用双光气并在 130 oc 或 150 oc 下加热 12 小时.该反应用于合成 4,6-二氯吡唑并[3,4-D]嘧啶(二氯-9H-异嘌呤).还描述了假定的机制.
Doi:10.1055/s-2005-922790
专利信息
专利号:US-6930113-B2
优先权日:1996-11-01
标题 :Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
发明人:GARVEY DAVID S; DE TEJADA INIGO SAENZ; EARL RICHARD A; KHANAPURE SUBHASH P
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).
专利号:US-2003158184-A1
优先权日:2001-12-21
标 题 :Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
发明人:GARVEY DAVID S; DE TEJADA INIGO SAENZ
摘要:The invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or release nitrogen monoxide, that induces the production of endogenous endothelium-derived relaxing factor, that stimulates endogenous synthesis of nitrogen monoxide, or that is a substrate for nitric oxide synthase. The methods may further comprise administering a therapeutically effective amount of a phosphodiesterase inhibitor and/or a nitrosated and/or nitrosylated phosphodiesterase inhibitor.
专利号:US-6472425-B1
优先权日:1997-10-31
标 题:Methods for treating female sexual dysfunctions
发明人:GARVEY DAVID S; SAENZ DE TEJADA INIGO
权利人:NITROMED INC
摘要:The present invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or releases nitrogen monoxide, that induces the production of endogenous endothelium-derived relaxing factor, that stimulates endogenous synthesis of nitrogen monoxide, or that is a substrate for nitric oxide synthase. The methods may further comprise administering a therapeutically effective amount of a phosphodiesterase inhibitor and/or a nitrosated and/or nitrosylated phosphodiesterase inhibitor.